Clinical Trial Update: A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial of BMS-582949 for moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BMS-582949

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis | Phase 2 | Status: COMPLETED